Low-Value Blood Culture Use in Adult Emergency Department Patients: A Scoping Review
Abstract
Background: Blood cultures (BCs) are used in emergency departments (EDs) to investigate and manage suspected sepsis; however, their inappropriate use contributes to low-value care, providing limited clinical benefit while causing avoidable harm. Despite recommendations for more selective testing, low-value blood culture (LVBC) use persists, and there remains uncertainty on the definition, drivers, and impact of LVBCs.
Objectives: To map the existing literature on LVBCs in adult ED patients, including definitions of LVBCs, associated clinical contexts, contributing factors, consequences and related gaps in knowledge.
Methods: Six databases were searched from inception to June 30, 2025. Studies involving adult populations and addressing LVBC use in EDs were included. Data were charted independently by two reviewers. Risk of bias was assessed using JBI critical appraisal tools.
Results: Of 1453 records screened, 18 studies were included in this scoping review. None defined LVBCs, although five themes characterising LVBCs emerged: limited impact on patient management, non-adherence to guidelines, failure to meet predictive tool thresholds, protocol-driven ordering, and BCs deemed unnecessary by clinicians. Reported prevalence of LVBCs ranged from 19% to 69%. The most referenced LVBC driver was pressure to comply with quality measures. Reported consequences of LVBCs included unnecessary treatment, investigation and prolonged stay due to false positive results. Patient-centred…
Read the paper
Related studies
- The Matrisome: In Silico Definition and In Vivo Characterization by Proteomics of Normal and Tumor Extracellular Matrices
- The Escherichia coli MG1655 in silico metabolic genotype: Its definition, characteristics, and capabilities
- In silico pharmacology for drug discovery: methods for virtual ligand screening and profiling
- In silico prediction of splice-altering single nucleotide variants in the human genome
- In silico clinical trials: how computer simulation will transform the biomedical industry
- In silico optimization of a guava antimicrobial peptide enables combinatorial exploration for peptide design
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.